본문 바로가기
KERD
논문KCI 등재

Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease

Hsiao Shun-Wen|Yen Hsu-Heng|Chen Yang-Yuan
거트앤리버 소화기연관학회협의회|2022.11|Gut and Liver|제16권 제6호|pp. 840-848|DOI 10.5009/gnl210479

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Ulcerative colitisInflammatory bowel diseaseCrohn disease

초록

The association between inflammatory bowel disease and colorectal cancer is well known. Although the overall incidence of inflammatory bowel disease has declined recently, patients with this disease still have a 1.7-fold increased risk of colorectal cancer. The risk factors for developing colorectal cancer include extensive colitis, young age at diagnosis, disease duration, primary sclerosing cholangitis, chronic colonic mucosal inflammation, dysplasia lesion, and post-inflammatory polyps. In patients with inflammatory bowel disease, control of chronic inflammation and surveillance colonoscopies are important for the prevention of colorectal cancer. The 2017 guidelines from the European Crohn’s and Colitis Organisation suggest that colonoscopies to screen for colorectal cancer should be performed when inflammatory bowel disease symptoms have lasted for 8 years. Current evidence supports the use of chemoprevention therapy with mesalamine to reduce the risk of colorectal cancer in patients with ulcerative colitis. Other compounds, including thiopurine, folic acid, statin, and tumor necrosis factor-α inhibitor, are controversial. Large surveillance cohort studies with longer follow-up duration are needed to evaluate the impact of drugs on colorectal cancer risks.

Abstract

The association between inflammatory bowel disease and colorectal cancer is well known. Although the overall incidence of inflammatory bowel disease has declined recently, patients with this disease still have a 1.7-fold increased risk of colorectal cancer. The risk factors for developing colorectal cancer include extensive colitis, young age at diagnosis, disease duration, primary sclerosing cholangitis, chronic colonic mucosal inflammation, dysplasia lesion, and post-inflammatory polyps. In patients with inflammatory bowel disease, control of chronic inflammation and surveillance colonoscopies are important for the prevention of colorectal cancer. The 2017 guidelines from the European Crohn’s and Colitis Organisation suggest that colonoscopies to screen for colorectal cancer should be performed when inflammatory bowel disease symptoms have lasted for 8 years. Current evidence supports the use of chemoprevention therapy with mesalamine to reduce the risk of colorectal cancer in patients with ulcerative colitis. Other compounds, including thiopurine, folic acid, statin, and tumor necrosis factor-α inhibitor, are controversial. Large surveillance cohort studies with longer follow-up duration are needed to evaluate the impact of drugs on colorectal cancer risks.

참고문헌 (99)

  1. Shu-Chen Wei, "Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease", Intestinal research, 15(3), pp.266~284 (2017), 대한장연구학회
  2. Yen HH, "Clinical features and treatment of inflammatory bowel disease in a lowincidence area: a hospital-based retrospective cohort study in Taiwan", Medicine (Baltimore), 100, pp.e25090~ (2021)
  3. Yen HH, "Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology : a Taiwanese retrospective cohort study", PLoS One, 16, pp.e0252286~ (2021)
  4. Yen HH, "Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis : a retrospective cohort analysis", PeerJ, 8, pp.e9537~ (2020)
  5. Hsu-Heng Yen, "Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population-based study", Intestinal research, 17(1), pp.54~62 (2019), 대한장연구학회[DOI]
  6. Eaden JA, "The risk of colorectal cancer in ulcerative colitis : a meta-analysis", Gut, 48, pp.526~535 (2001)
  7. Söderlund S, "Decreasing timetrends of colorectal cancer in a large cohort of patients with inflammatory bowel disease", Gastroenterology, 136, pp.1561~1567 (2009)
  8. Jess T, "Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years", Gastroenterology, 143, pp.375~381 (2012)
  9. Palli D, "Hodgkin's disease risk is increased in patients with ulcerative colitis", Gastroenterology, 119, pp.647~653 (2000)
  10. Bernstein CN, "Cancer risk in patients with inflammatory bowel disease : a populationbased study", Cancer, 91, pp.854~862 (2001)
  11. Winther KV, "Long-term risk of cancer in ulcerative colitis : a populationbased cohort study from Copenhagen County", Clin Gastroenterol Hepatol, 2, pp.1088~1095 (2004)
  12. Jess T, "Risk of intestinal cancer in inflammatory bowel disease : a population-based study from Olmsted county, Minnesota", Gastroenterology, 130, pp.1039~1046 (2006)
  13. Jess T, "Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades : a population-based study from Copenhagen, Denmark", Inflamm Bowel Dis, 13, pp.481~489 (2007)
  14. Lutgens MW, "Declining risk of colorectal cancer in inflammatory bowel disease : an updated metaanalysis of population-based cohort studies", Inflamm Bowel Dis, 19, pp.789~799 (2013)
  15. Itzkowitz SH, "Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease : the role of inflammation", Am J Physiol Gastrointest Liver Physiol, 287, pp.G7~G17 (2004)
  16. Feagins LA, "Carcinogenesis in IBD : potential targets for the prevention of colorectal cancer", Nat Rev Gastroenterol Hepatol, 6, pp.297~305 (2009)
  17. McConnell BB, "The role of inflammation in the pathogenesis of colorectal cancer", Curr Colorectal Cancer Rep, 5, pp.69~74 (2009)
  18. Dirisina R, "p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis", Gastroenterology, 141, pp.1036~1045 (2011)
  19. Mattar MC, "Current management of inflammatory bowel disease and colorectal cancer", Gastrointest Cancer Res, 4, pp.53~61 (2011)
  20. Bezzio C, "Chemoprevention of colorectal cancer in ulcerative colitis : digging deep in current evidence", Expert Rev Gastroenterol Hepatol, 11, pp.339~347 (2017)
  21. Magro F, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1 : definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders", J Crohns Colitis, 11, pp.649~670 (2017)
  22. Choi CH, "Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis : an updated overview", Am J Gastroenterol, 110, pp.1022~1034 (2015)
  23. Selinger CP, "Long-term follow-up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease", Clin Gastroenterol Hepatol, 12, pp.644~650 (2014)
  24. Lennard-Jones JE, "Cancer surveillance in ulcerative colitis. Experience over 15years", Lancet, 2, pp.149~152 (1983)
  25. Mathy C, "Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis", Inflamm Bowel Dis, 9, pp.351~355 (2003)
  26. Choi CH, "Low-grade dysplasia in ulcerative colitis : risk factors for developing high-grade dysplasia or colorectal cancer", Am J Gastroenterol, 110, pp.1461~1471 (2015)
  27. Claessen MM, "More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis", Inflamm Bowel Dis, 15, pp.1331~1336 (2009)
  28. Jayaram H, "Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis : fact or fiction?", Gut, 48, pp.430~434 (2001)
  29. Kappelman MD, "Risk of cancer in patients with inflammatory bowel diseases : a nationwide population-based cohort study with 30 years of follow-up evaluation", Clin Gastroenterol Hepatol, 12, pp.265~273 (2014)
  30. Nuako KW, "Familial predisposition for colorectal cancer in chronic ulcerative colitis : a case-control study", Gastroenterology, 115, pp.1079~1083 (1998)
  31. Koutroubakis IE, "Multiyear patterns of serum inflammatory biomarkers and risk of colorectal neoplasia in patients with ulcerative colitis", Inflamm Bowel Dis, 22, pp.100~105 (2016)
  32. Sonnenberg A, "Epithelial dysplasia and cancer in IBD strictures", J Crohns Colitis, 9, pp.769~775 (2015)
  33. Fumery M, "Detection of dysplasia or cancer in 3. 5% of patients with inflammatory bowel disease and colonic strictures", Clin Gastroenterol Hepatol, 13, pp.1770~1775 (2015)
  34. Wijnands AM, "Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease : systematic review and meta-analysis", Gastroenterology, 160, pp.1584~1598 (2021)
  35. Bye WA, "Strategies for detecting colorectal cancer in patients with inflammatory bowel disease : a Cochrane systematic review and meta-analysis", Am J Gastroenterol, 113, pp.1801~1809 (2018)
  36. Feuerstein JD, "Meta-analysis of dye-based chromoendoscopy compared with standard-and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer", Gastrointest Endosc, 90, pp.186~195 (2019)
  37. Watanabe T, "Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer", Gastroenterology, 151, pp.1122~1130 (2016)
  38. Yen HH, "Performance comparison of the deep learning and the human endoscopist for bleeding peptic ulcer disease", J Med Biol Eng, 41, pp.504~513 (2021)
  39. Huang TY, "Accurate diagnosis of endoscopic mucosal healing in ulcerative colitis using deep learning and machine learning", J Chin Med Assoc, 84, pp.678~681 (2021)
  40. Correia FP, "Artificial intelligence application in diagnostic gastrointestinal endoscopy-Deus ex machina?", World J Gastroenterol, 27, pp.5351~5361 (2021)
  41. Chang YY, "Deep learning-based endoscopic anatomy classification : an accelerated approach for data preparation and model validation", Surg Endosc, 36, pp.3811~3821 (2022)
  42. Yen HH, "Current status and future perspective of artificial intelligence in the management of peptic ulcer bleeding : a review of recent literature", J Clin Med, 10, pp.3527~ (2021)
  43. Chang YY, "Upper endoscopy photodocumentation quality evaluation with novel deep learning system", Dig Endosc, 34, pp.994~1001 (2022)
  44. Gutierrez Becker B, "Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data", Ther Adv Gastrointest Endosc, 14, pp.2631774521990623~ (2021)
  45. Maeda Y, "Can artificial intelligence help to detect dysplasia in patients with ulcerative colitis", Endoscopy, 53, pp.E273~E274 (2021)
  46. Pinczowski D, "Risk factors for colorectal cancer in patients with ulcerative colitis : a case-control study", Gastroenterology, 107, pp.117~120 (1994)
  47. Lyakhovich A, "Systematic review : molecular chemoprevention of colorectal malignancy by mesalazine", Aliment Pharmacol Ther, 31, pp.202~209 (2010)
  48. Luciani MG, "5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint", Gastroenterology, 132, pp.221~235 (2007)
  49. Gasche C, "Mesalazine improves replication fidelity in cultured colorectal cells", Cancer Res, 65, pp.3993~3997 (2005)
  50. Mantena SK, "In vivo radioprotection by 5-aminosalicylic acid", Mutat Res, 650, pp.63~79 (2008)
  51. Nandi J, "5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats", Dig Dis Sci, 53, pp.123~132 (2008)
  52. Monteleone G, "Silencing of SHPTP2defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells", Cell Death Differ, 13, pp.202~211 (2006)
  53. Chu EC, "Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action", Aliment Pharmacol Ther, 25, pp.1443~1449 (2007)
  54. Bos CL, "Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt", beta-catenin pathway activity, 2006, pp.27, 2371~2382
  55. StolfiC, "Molecular basis of the potential of mesalazine to prevent colorectal cancer", World J Gastroenterol, 14, pp.4434~4439 (2008)
  56. Song M, "Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats", Postgrad Med J, 82, pp.130~135 (2006)
  57. Carrat F, "The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease", Aliment Pharmacol Ther, 45, pp.533~541 (2017)
  58. Mak J, "Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients : a population-based cohort study", Scand J Gastroenterol, 55, pp.279~286 (2020)
  59. Qiu X, "Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia : a systematic review with meta-analysis", Oncotarget, 8, pp.1031~1045 (2017)
  60. Bonovas S, "Systematic review with meta-analysis : use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease", Aliment Pharmacol Ther, 45, pp.1179~1192 (2017)
  61. O’Connor A, "Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease : an agent-specific systematic review and meta-analysis", Inflamm Bowel Dis, 21, pp.2562~2569 (2015)
  62. Harbord M, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2 : current management", J Crohns Colitis, 11, pp.769~784 (2017)
  63. Torres J, "ECCO guidelines on therapeutics in Crohn's disease : medical treatment", J Crohns Colitis, 14, pp.4~22 (2020)
  64. Beaugerie L, "Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease", Gastroenterology, 145, pp.166~175 (2013)
  65. Beaugerie L, "Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease : a prospective observational cohort study", Lancet, 374, pp.1617~1625 (2009)
  66. Lu MJ, "Systematic review with meta-analysis : thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease", Aliment Pharmacol Ther, 47, pp.318~331 (2018)
  67. Zhu Z, "Reduced risk of inflammatory bowel disease-associated colorectal neoplasia with use of thiopurines : a systematic review and meta-analysis", J Crohns Colitis, 12, pp.546~558 (2018)
  68. Dobrzycka M, "Statins and colorectal cancer : a systematic review", Exp Clin Endocrinol Diabetes, 128, pp.255~262 (2020)
  69. Qi XF, "Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells", Toxicol Lett, 199, pp.277~287 (2010)
  70. Bergman M, "Statins as modulators of colon cancer cells induced cytokine secretion by human PBMC", Vascul Pharmacol, 54, pp.88~92 (2011)
  71. Ishikawa S, "Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer", Int J Cancer, 135, pp.2528~2536 (2014)
  72. Lim T, "Synergistic effect of simvastatin plus radiation in gastric cancer and colorectal cancer : implications of BIRC5 and connective tissue growth factor", Int J Radiat Oncol Biol Phys, 93, pp.316~325 (2015)
  73. Samadder NJ, "Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use", Cancer, 117, pp.1640~1648 (2011)
  74. Ananthakrishnan AN, "Statin use is associated with reduced risk of colorectal cancer in patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 14, pp.973~979 (2016)
  75. Shailja C. Shah, "Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease", Gut and Liver, 13(1), pp.54~61 (2019), 거트앤리버 소화기연관학회협의회[DOI]
  76. Singh S, "Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis : a systematic review and meta-analysis", Liver Transpl, 19, pp.1361~1369 (2013)
  77. Khaderi SA, "Screening for malignancy in primary sclerosing cholangitis(PSC)", Curr Gastroenterol Rep, 17, pp.17~ (2015)
  78. Boonstra K, "Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis", Hepatology, 58, pp.2045~2055 (2013)
  79. Soetikno RM, "Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis : a meta-analysis", Gastrointest Endosc, 56, pp.48~54 (2002)
  80. Singh S, "Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease : a systematic review and metaanalysis", Inflamm Bowel Dis, 19, pp.1631~1638 (2013)
  81. Nagengast FM, "Role of bile acids in colorectal carcinogenesis", Eur J Cancer, 31A, pp.1067~1070 (1995)
  82. Tung BY, "Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis", Ann Intern Med, 134, pp.89~95 (2001)
  83. Kim YJ, "Prevention of colitis-associated carcinogenesis with infliximab", Cancer Prev Res(Phila), 3, pp.1314~1333 (2010)
  84. Kopylov U, "Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics : a Quebec claims database study", Inflamm Bowel Dis, 21, pp.1847~1853 (2015)
  85. Baars JE, "The risk of inflammatory bowel disease-related colorectal carcinoma is limited : results from a nationwide nested case-control study", Am J Gastroenterol, 106, pp.319~328 (2011)
  86. Alkhayyat M, "Lower rates of colorectal cancer in patients with inflammatory bowel disease using anti-TNF therapy", Inflamm Bowel Dis, 27, pp.1052~1060 (2021)
  87. Raine T, "ECCO guidelines on therapeutics in ulcerative colitis : medical treatment", J Crohns Colitis, 16, pp.2~17 (2022)
  88. Freudenheim JL, "Folate intake and carcinogenesis of the colon and rectum", Int J Epidemiol, 20, pp.368~374 (1991)
  89. Wien TN, "Cancer risk with folic acid supplements : a systematic review and meta-analysis", BMJ Open, 2, pp.e000653~ (2012)
  90. Jonathan Potack, "Colorectal Cancer in Inflammatory Bowel Disease", Gut and Liver, 2(2), pp.61~73 (2008), 거트앤리버 소화기연관학회협의회
  91. Swinson CM, "Role of sulphasalazine in the aetiology of folate deficiency in ulcerative colitis", Gut, 22, pp.456~461 (1981)
  92. Burr NE, "Folic acid supplementation may reduce colorectal cancer risk in patients with inflammatory bowel disease : a systematic review and metaanalysis", J Clin Gastroenterol, 51, pp.247~253 (2017)
  93. Velayos FS, "Predictive and protective factors associated with colorectal cancer in ulcerative colitis : a case-control study", Gastroenterology, 130, pp.1941~1949 (2006)
  94. Rubin DT, "Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis : a case-control study", Clin Gastroenterol Hepatol, 11, pp.1601~1608 (2013)
  95. Burr NE, "Does aspirin or nonaspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease", World J Gastroenterol, 22, pp.3679~3686 (2016)
  96. Bosetti C, "Aspirin and the risk of colorectal and other digestive tract cancers : an updated meta-analysis through 2019", Ann Oncol, 31, pp.558~568 (2020)
  97. Lamb CA, "British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults", Gut, 68(Suppl 3), pp.s1~s106 (2019)
  98. Nakase H, "Evidence-based clinical practice guidelines for inflammatory bowel disease 2020", J Gastroenterol, 56, pp.489~526 (2021)
  99. Rubin DT, "ACG clinical guideline : ulcerative colitis in adults", Am J Gastroenterol, 114, pp.384~413 (2019)

관련 논문AI추천

Colon Cancer Screening and Surveillance in Inflammatory Bowel DiseaseSong I Bae, You Sun Kim대한소화기내시경학회 · Clinical Endoscopy2014 · 제47권 제6호Recent advances in surveillance colonoscopy for dysplasia in inflammatory bowel diseaseSoo-Young Na, Won Moon대한소화기내시경학회 · Clinical Endoscopy2022 · 제55권 제6호Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel DiseaseAkash Kumar, Daniel Castaneda, Gennaro Giustino, Jason Glass, Joana Torres, Jordan Elman, Joren R. ten Hove, Shailja C. Shah, Steven H. Itzkowitz, Thomas A. Ullman거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제1호Medications and the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Use of the Landmark Method강대용, 김동욱, 김현수, 김희만, 이정국, 최윤영연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제11호Can Statin Prevent the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Disease?Hyun Joo Jang거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제2호Risk Factors of Colorectal Stricture Associated with Developing High-Grade Dysplasia or Cancer in Ulcerative Colitis: A Multicenter Long-term Follow-up StudyJie Zhong, Long Cui, Peng Du, Weimin Xu, Wenjun Ding, Yubei Gu거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제5호

이 간행물의 다른 논문 (18건)

Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-EfficiencyKim Gwang Ha, Lee Moon Wonpp. 807-808How to Optimize the Care Cascade of Hepatitis C Virus InfectionKim Beom Kyungpp. 809-810Forthcoming Step in Gastric Cancer Prevention: How Can Risk Stratification Be Combined with Endoscopic Screening for Gastric Cancer?Hamashima Chisatopp. 811-824A New Paradigm Shift in Gastroparesis ManagementRerknimitr Rungsun, Mekaroonkamol Parit, Tiankanon Kaseneepp. 825-839Prolonged QT Interval in Cirrhosis: Twisting Time?Lee William, Vandenberk Bert, Raj Satish R., Lee Samuel S.pp. 849-860
원문 보기